CytRx Corporation , a biopharmaceutical research and development company specializing in oncology , today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma .
http://ift.tt/1at02t1
http://ift.tt/1at02t1
No comments:
Post a Comment